Safety tracking study for Beyfortus in Korean children
Treatments studied
Part of Lungs & breathing clinical trials.
This study monitors the safety of Beyfortus (nirsevimab) in children up to 2 years old who have already received it as prescribed. It helps make sure the medicine is safe and works well in real-world use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is up to 24 months old (2 years) and received Beyfortus as prescribed by their doctor.
- You or the legal guardian must sign a consent form allowing your child to join.
- Your child is not currently in any other study for vaccines, drugs, devices, or procedures, or hasn't been in one in the past 4 weeks.
- Your child does not have any medical condition that would make Beyfortus unsafe for them, according to the approved label.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new RSV vaccine in two phases. First, it will be given to healthy adults 18 and older to check safety. Then, it will be studied in adults 50 and older, including those with stable health conditions, to see if it helps protect against RSV, a common virus that can cause serious breathing problems in older people.
This trial looks at how well the drug nirsevimab works for babies hospitalized with RSV bronchiolitis. It also studies the body's immune response and the baby's environment. The goal is to see if nirsevimab can help infants recover from this serious lung infection.
This study looks at how well the new nirsevimab vaccine works against bronchiolitis in babies. If your infant has their first bout of bronchiolitis and gets a nose swab, they may be able to help researchers understand how the virus spreads and how to better protect other babies.
This study looks at whether the drug nirsevimab can reduce hospitalizations caused by RSV (a common respiratory virus) in babies under 1 year old. If your baby has a lung infection like bronchiolitis or pneumonia, this trial may help understand how well the medicine works.
This trial tests a new medicine called SIBP-A16 to help protect infants from RSV, a common virus that can cause serious breathing problems. It is for preterm and full-term infants under 1 year old who are entering their first RSV season.
This study is watching babies under 1 year old who are in the hospital with bronchiolitis. Doctors want to learn more about the virus and how the new preventive shot (nirsevimab) is working.
Hear when a new Respiratory Syncytial Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.